{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:23:32Z","timestamp":1770290612373,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s11255-019-02191-5","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T10:03:09Z","timestamp":1560247389000},"page":"1667-1673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dialysate copeptin and peritoneal transport in incident peritoneal dialysis patients"],"prefix":"10.1007","volume":"51","author":[{"given":"Maciej","family":"Fija\u0142kowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Safranow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Ciechanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Muraszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Do\u0142\u0119gowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Do\u0142\u0119gowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6461-1570","authenticated-orcid":false,"given":"Edyta","family":"Golembiewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"issue":"2","key":"2191_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.dsx.2017.09.003","volume":"12","author":"AAD Allawi","year":"2018","unstructured":"Allawi AAD (2018) Malnutrition, inflamation and atherosclerosis (MIA syndrome) in patients with end stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr 12(2):91\u201397","journal-title":"Diabetes Metab Syndr"},{"issue":"12","key":"2191_CR2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1681\/ASN.2013030314","volume":"24","author":"M Lambie","year":"2013","unstructured":"Lambie M et al (2013) Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 24(12):2071\u20132080","journal-title":"J Am Soc Nephrol"},{"key":"2191_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000479254","volume":"191","author":"L Dai","year":"2017","unstructured":"Dai L et al (2017) End-stage renal disease, inflammation and cardiovascular outcomes. Contrib Nephrol 191:32\u201343","journal-title":"Contrib Nephrol"},{"issue":"Suppl 5","key":"2191_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ndt\/16.suppl_5.61","volume":"16","author":"PG Blake","year":"2001","unstructured":"Blake PG (2001) Integrated end-stage renal disease care: the role of peritoneal dialysis. Nephrol Dial Transpl 16(Suppl 5):61\u201366","journal-title":"Nephrol Dial Transpl"},{"key":"2191_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cca.2013.12.003","volume":"430","author":"MS Velloso","year":"2014","unstructured":"Velloso MS et al (2014) Peritoneal dialysis and inflammation. Clin Chim Acta 430:109\u2013114","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2191_CR6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/089686080502500509","volume":"25","author":"TA Martikainen","year":"2005","unstructured":"Martikainen TA et al (2005) Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 25(5):453\u2013460","journal-title":"Perit Dial Int"},{"issue":"2\u20133","key":"2191_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000169582","volume":"7","author":"ZJ Twardowski","year":"1989","unstructured":"Twardowski ZJ (1989) Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 7(2\u20133):95\u2013108","journal-title":"Blood Purif"},{"key":"2191_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2369-15-8","volume":"15","author":"Y Cho","year":"2014","unstructured":"Cho Y et al (2014) Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. BMC Nephrol 15:8","journal-title":"BMC Nephrol"},{"issue":"3","key":"2191_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1432-1033.1972.tb01918.x","volume":"28","author":"DA Holwerda","year":"1972","unstructured":"Holwerda DA (1972) A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem 28(3):334\u2013339","journal-title":"Eur J Biochem"},{"issue":"1","key":"2191_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG et al (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112\u2013119","journal-title":"Clin Chem"},{"issue":"3","key":"2191_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrendo.2015.224","volume":"12","author":"M Christ-Crain","year":"2016","unstructured":"Christ-Crain M, Fenske W (2016) Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 12(3):168\u2013176","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2191_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/ndt\/gfy017","volume":"34","author":"S Enh\u00f6rning","year":"2019","unstructured":"Enh\u00f6rning S, Christensson A, Melander O (2019) Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transpl 34(1):74\u201382","journal-title":"Nephrol Dial Transpl"},{"key":"2191_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40885-017-0068-y","volume":"23","author":"B Afsar","year":"2017","unstructured":"Afsar B (2017) Pathophysiology of copeptin in kidney disease and hypertension. Clin Hypertens 23:13","journal-title":"Clin Hypertens"},{"issue":"12","key":"2191_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2174\/1389203718666170717095301","volume":"18","author":"E Golembiewska","year":"2017","unstructured":"Golembiewska E et al (2017) Prognostic value of copeptin in chronic kidney disease: from general population to end-stage renal disease. Curr Protein Pept Sci 18(12):1232\u20131243","journal-title":"Curr Protein Pept Sci"},{"issue":"3","key":"2191_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/CS20080140","volume":"116","author":"SS Bhandari","year":"2009","unstructured":"Bhandari SS et al (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257\u2013263","journal-title":"Clin Sci (Lond)"},{"key":"2191_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/5584_2018_189","volume":"1096","author":"S Niemczyk","year":"2018","unstructured":"Niemczyk S et al (2018) Copeptin blood content as a diagnostic marker of chronic kidney disease. Adv Exp Med Biol 1096:83\u201391","journal-title":"Adv Exp Med Biol"},{"key":"2191_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121479","author":"R El Boustany","year":"2018","unstructured":"El Boustany R et al (2018) Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population. JCI Insight. \n                    https:\/\/doi.org\/10.1172\/jci.insight.121479","journal-title":"JCI Insight"},{"issue":"suppl_1","key":"2191_CR18","first-page":"146","volume":"32","author":"D Zittema","year":"2017","unstructured":"Zittema D et al (2017) Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. Nephrol Dial Transpl 32(suppl_1):146\u2013153","journal-title":"Nephrol Dial Transpl"},{"issue":"11","key":"2191_CR19","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","volume":"27","author":"WE Boertien","year":"2012","unstructured":"Boertien WE et al (2012) Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl 27(11):4131\u20134137","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"2191_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5414\/CN108894","volume":"86","author":"V Corradi","year":"2016","unstructured":"Corradi V et al (2016) Copeptin levels and kidney function in ADPKD: case-control study. Clin Nephrol 86(9):147\u2013153","journal-title":"Clin Nephrol"},{"issue":"4","key":"2191_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","volume":"88","author":"E Meijer","year":"2009","unstructured":"Meijer E et al (2009) Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88(4):561\u2013567","journal-title":"Transplantation"},{"issue":"4","key":"2191_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3349\/ymj.2015.56.4.976","volume":"56","author":"JS Kim","year":"2015","unstructured":"Kim JS et al (2015) Copeptin in hemodialysis patients with left ventricular dysfunction. Yonsei Med J 56(4):976\u2013980","journal-title":"Yonsei Med J"},{"issue":"1","key":"2191_CR23","doi-asserted-by":"publisher","first-page":"e86148","DOI":"10.1371\/journal.pone.0086148","volume":"9","author":"F Artunc","year":"2014","unstructured":"Artunc F et al (2014) Plasma concentrations of the vasoactive peptide fragments mid-regional pro-adrenomedullin, C-terminal pro-endothelin 1 and copeptin in hemodialysis patients: associated factors and prediction of mortality. PLoS One 9(1):e86148","journal-title":"PLoS One"},{"issue":"5","key":"2191_CR24","doi-asserted-by":"publisher","first-page":"e0127116","DOI":"10.1371\/journal.pone.0127116","volume":"10","author":"EM Ettema","year":"2015","unstructured":"Ettema EM et al (2015) Changes in plasma copeptin levels during hemodialysis: are the physiological stimuli active in hemodialysis patients? PLoS One 10(5):e0127116","journal-title":"PLoS One"},{"issue":"3","key":"2191_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ekir.2017.01.006","volume":"2","author":"EM Ettema","year":"2017","unstructured":"Ettema EM et al (2017) The effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels. Kidney Int Rep 2(3):410\u2013419","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2191_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12882-017-0589-3","volume":"18","author":"FM Rasche","year":"2017","unstructured":"Rasche FM et al (2017) Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients. BMC Nephrol 18(1):175","journal-title":"BMC Nephrol"},{"issue":"1","key":"2191_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/089686080602600109","volume":"26","author":"R Pecoits-Filho","year":"2006","unstructured":"Pecoits-Filho R et al (2006) Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 26(1):53\u201363","journal-title":"Perit Dial Int"},{"issue":"5","key":"2191_CR28","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/ndt\/gfp670","volume":"25","author":"KH Oh","year":"2010","unstructured":"Oh KH et al (2010) Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients. Nephrol Dial Transpl 25(5):1639\u20131646","journal-title":"Nephrol Dial Transpl"},{"key":"2191_CR29","doi-asserted-by":"publisher","first-page":"d194","DOI":"10.2741\/A274","volume":"3","author":"RA Nemenoff","year":"1998","unstructured":"Nemenoff RA (1998) Vasopressin signaling pathways in vascular smooth muscle. Front Biosci 3:d194\u2013d207","journal-title":"Front Biosci"},{"issue":"3 Pt 1","key":"2191_CR30","doi-asserted-by":"publisher","first-page":"C654","DOI":"10.1152\/ajpcell.1994.266.3.C654","volume":"266","author":"M Spatz","year":"1994","unstructured":"Spatz M et al (1994) Vasoconstrictive peptides induce endothelin-1 and prostanoids in human cerebromicrovascular endothelium. Am J Physiol 266(3 Pt 1):C654\u2013C660","journal-title":"Am J Physiol"},{"issue":"1","key":"2191_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12882-016-0406-4","volume":"17","author":"I Kocyigit","year":"2016","unstructured":"Kocyigit I et al (2016) Vasopressin-related copeptin is a novel predictor of early endothelial dysfunction in patients with adult polycystic kidney disease. BMC Nephrol 17(1):196","journal-title":"BMC Nephrol"},{"issue":"11","key":"2191_CR32","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1172\/JCI106742","volume":"50","author":"LW Henderson","year":"1971","unstructured":"Henderson LW, Kintzel JE (1971) Influence of antidiuretic hormone on peritoneal membrane area and permeability. J Clin Invest 50(11):2437\u20132443","journal-title":"J Clin Invest"},{"issue":"3","key":"2191_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/089686080802800316","volume":"28","author":"ER Zakaria","year":"2008","unstructured":"Zakaria ER et al (2008) Vasoactive components of dialysis solution. Perit Dial Int 28(3):283\u2013295","journal-title":"Perit Dial Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02191-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:20:33Z","timestamp":1591744833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02191-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02191-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bengt Lindholm is employed by Baxter Healthcare. None of the other authors declare any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}